Hematology\Oncology Clinic

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

E O’Brien, Nely Wigler, Moshe Inbar et al. · Annals of Oncology · 2004 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +17

Heterozygous splice mutation in <i>PIK3R1</i> causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K

C. Lucas, Yu Zhang, Anthony Venida et al. · The Journal of Experimental Medicine · 2014 · 285 citations · Full text

Life Sciences, Immunology, Molecular Genetics +17

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

Elizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels et al. · Journal for ImmunoTherapy of Cancer · 2019 · 147 citations · Full text

Medicine, Immunology, Oncology +14

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Alessio Cortellini, Massimo Di Maïo, Olga Nigro et al. · Journal for ImmunoTherapy of Cancer · 2021 · 144 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

Ajjai Alva, Gregory A. Daniels, Michael K. Wong et al. · Cancer Immunology Immunotherapy · 2016 · 104 citations · Full text

Life Sciences, Immunology, Oncology +17